COMPREHENSIVE ANALYSIS OF POPULATION KINETIC SOFTWARE NONMEM

药物治疗许多问题（癌症，艾滋病，传染病， 移植、心血管疾病、中风等）也是有限的 通常是药物中毒。 治疗可以针对个人进行优化 患者通过定量描述剂量之间的关系， 药物暴露（血清水平和/或血清水平曲线下面积， AUQ和效果，如细菌，病毒和取消细胞生长和 杀人，正如Zhi（和许多其他）模型所描述的那样，以及那些 药物暴露和毒性之间的联系 发展 量效关系允许合理选择靶点 治疗目标，如血清药物水平或谱，或药物 效果，从而允许剂量进行优化，并与 实现最佳精度。 这种优化的药物治疗的障碍是缺乏 剂量-浓度-效应关系从以下人群中发展而来： 在相关的现实生活临床护理情况下研究的患者。 群体药代动力学和动力学建模是消除 这个屏障。

Drug therapy for many problems (cancer, AIDS, infectious disease, transplants, cardiovascular disease, stroke, etc.) is limited too often by drug toxicity. Therapy can be optimized for an individual patient by describing quantitatively the relationships between dose, drug exposure (serum levels and/or area under the serum level curve, AUQ and effect, such as bacterial, viral and cancel cell growth and killing, as described by Zhi (and many other) models, as well as those between drug exposure and toxicity. Development of dose-exposureeffect relationships allows rational selection of target therapeutic goals such as serum drug levels or profiles, or drug effects, and thus permits dosing to proceed optimally, and with optimal precision in their achievement. The barrier to such optimized drug therapy has been the lack of dose-concentration-effect relationships developed from populations of patients studied in their relevant real-life clinical care situations. Population pharmacokinetic and dynamic modeling is the tool to remove this barrier.